Business news

    Neuroscientific Biopharmaceuticals (ASX:NSB) finds positive effect in MS animal study

    Article Image

    NeuroScientific Biopharmaceuticals (ASX:NSB) has announced positive results of its lead drug candidate EmtinB™ in a gold standard animal model of Multiple Sclerosis.

    The study evaluated EmtinB™ across three dose groups, including 10mg/kg and 20mg/kg dosed daily, and an exploratory group of 40mg/kg dosed once every 3 days.

    The results of the study suggest EmtinB™ is a neuroprotective agent and treatment for neurodegenerative diseases, such as Multiple Sclerosis, with a likely target therapeutic dose range of 10-20mg/kg in a mouse (equivalent to an adult human dose range of 50mg to 115mg).

    Following the announcement, shares of Neuroscientific Biopharmaceuticals were unchanged at $0.097.

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa